Navitoclax thrombocytopenia
Web开馆时间：周一至周日7:00-22:30 周五 7:00-12:00; 我的图书馆
Navitoclax thrombocytopenia
Did you know?
WebSeventeen patients (65.4%) experienced grade 3/4 AEs related to navitoclax, with thrombocytopenia (38.5%) and neutropenia (30.8%) being most common. Serious related AEs were reported in 2 patients (bacterial sepsis and increased white blood cell count [ n = 1 each]); none were fatal. Web18 de nov. de 2010 · Navitoclax has a novel mechanism of peripheral thrombocytopenia and T-cell lymphopenia, attributable to high-affinity inhibition of BCL-XL and BCL-2, respectively. On the basis of these findings, a 150 mg 7-day lead-in dose followed by a 325 mg dose administered on a continuous 21/21 dosing schedule was selected for phase 2 …
WebNavitoclax is relatively well tolerated in patients, with thrombocytopenia reported as the major adverse effect (Gandhi et al., 2011). Investigators have begun testing these … Web14 de abr. de 2024 · Navitoclax and docetaxel induce thrombocytopenia via different mechanisms; therefore, the combination was expected to significantly lower the platelet …
WebThose AEs noted more frequently by patients treated with navitoclax included thrombocytopenia, neutropenia and elevations in hepatic transaminases. Navitoclax … Web15 de mar. de 2024 · A proapoptotic effect from navitoclax was demonstrated by early-onset thrombocytopenia. Conclusions: Oral combination therapy with navitoclax and …
Web1 de mar. de 2011 · Navitoclax is safe and well tolerated, with dose-dependent thrombocytopenia as the major adverse effect. Preliminary efficacy data are encouraging in SCLC. Efficacy in SCLC and the utility of pro-GRP as a marker of treatment response will be further evaluated in phase II studies.
Web17 de mar. de 2014 · Clinical trials of navitoclax (ABT-263, which targets BCL-2, BCL-X L and BCL-W) have shown great promise, but encountered dose-limiting thrombocytopenia. Recent work has demonstrated that this... raj rajeshwari temple janakpuriWeb26 de nov. de 2024 · Transient thrombocytopenia and lymphopenia: Navitoclax inhibits BIM and antiapoptotic proteins interactions, which then stimulates the intrinsic apoptotic … rajramaWeb31 de ene. de 2011 · Navitoclax is an orally available analog of ABT-737, first described to cause mechanism-based killing of multiple SCLC cell lines and regression of tumor xenografts. 13, 14 These effects were also seen with navitoclax 15, 16 with significant tumor growth inhibition in nine of 11 tumor models and prolonged complete regression in … drenastinWeb26 de nov. de 2024 · Navitoclax is one of the B-cell lymphoma 2 (BCL-2) family protein inhibitors which has been generated during the clinical development of ABT-737 ( Tse et … raj rajeshwari temple uttarakhandWeb1 de mar. de 2011 · Navitoclax is safe and well tolerated, with dose-dependent thrombocytopenia as the major adverse effect. Preliminary efficacy data are … raj rajeshwar temple akolaWeb3 de may. de 2024 · Due to the known effects of navitoclax on platelet counts, patients with active bleeding or thrombocytopenia-associated bleeding within 1 year, active peptic ulcer disease or potentially hemorrhagic esophagitis or gastritis, a requirement for concurrent therapeutic anticoagulants, or a history of immune thrombocytopenic purpura, … raj rajpara mdWeb18 de nov. de 2011 · Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL), Thomas J. Kipps, M.D., Ph.D, Thomas J. Kipps, M.D., Ph.D 1The University of California, San Diego, La Jolla, CA, USA, raj rajeshwari temple konnagar